{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:42:15Z","timestamp":1776814935312,"version":"3.51.2"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-43240-1","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T05:24:06Z","timestamp":1773206646000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy of disease-modifying therapies in patients with clinically isolated syndrome: a systematic review and network meta-analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"Yanisa","family":"Chumpangern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanika","family":"Seawsirikul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panisara","family":"Keatbundit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leeyaporn","family":"Thongtem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekdanai","family":"Uawithya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roongnapa","family":"Khampang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatchaporn","family":"Ongphichetmetha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasitorn","family":"Siritho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naraporn","family":"Prayoonwiwat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiraporn","family":"Jitprapaikulsan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"14","key":"43240_CR1","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton, C. et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS. Mult Scler. 26(14), 1816\u20131821 (2020).","journal-title":"Mult Scler."},{"issue":"11","key":"43240_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041249","volume":"10","author":"I Gil-Gonzalez","year":"2020","unstructured":"Gil-Gonzalez, I. et al. Quality of life in adults with multiple sclerosis: A systematic review. BMJ Open 10(11), e041249 (2020).","journal-title":"BMJ Open"},{"issue":"2","key":"43240_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/neurolint13020022","volume":"13","author":"AA Berger","year":"2021","unstructured":"Berger, A. A. et al. Monomethyl fumarate (MMF, Bafiertam) for the treatment of relapsing forms of multiple sclerosis (MS). Neurol. Int. 13(2), 207\u2013223 (2021).","journal-title":"Neurol. Int."},{"issue":"3","key":"43240_CR4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3), 278\u2013286 (2014).","journal-title":"Neurology"},{"issue":"5","key":"43240_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S1474-4422(05)70071-5","volume":"4","author":"D Miller","year":"2005","unstructured":"Miller, D. et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: Natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 4(5), 281\u2013288 (2005).","journal-title":"Lancet Neurol."},{"issue":"6","key":"43240_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/1756285610385608","volume":"3","author":"R Gold","year":"2010","unstructured":"Gold, R. et al. Evolving expectations around early management of multiple sclerosis. Ther. Adv. Neurol. Disord. 3(6), 351\u2013367 (2010).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"43240_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58091178","author":"R Balnyt\u0117","year":"2022","unstructured":"Balnyt\u0117, R. et al. Factors related to the progression of clinically isolated syndrome to multiple sclerosis: A retrospective study in Lithuania. Medicina (Kaunas) https:\/\/doi.org\/10.3390\/medicina58091178 (2022).","journal-title":"Medicina (Kaunas)"},{"issue":"Suppl 1","key":"43240_CR8","first-page":"S1","volume":"52","author":"H Efendi","year":"2015","unstructured":"Efendi, H. Clinically isolated syndromes: Clinical characteristics, differential diagnosis, and management. Noro Psikiyatr. Ars. 52(Suppl 1), S1-s11 (2015).","journal-title":"Noro Psikiyatr. Ars."},{"issue":"2","key":"43240_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2), 162\u2013173 (2018).","journal-title":"Lancet Neurol"},{"issue":"1","key":"43240_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2217\/nmt-2021-0058","volume":"13","author":"M Amin","year":"2023","unstructured":"Amin, M. & Hersh, C. M. Updates and advances in multiple sclerosis neurotherapeutics. Neurodegener. Dis. Manag. 13(1), 47\u201370 (2023).","journal-title":"Neurodegener. Dis. Manag."},{"issue":"5","key":"43240_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103312","volume":"22","author":"FF Konen","year":"2023","unstructured":"Konen, F. F. et al. Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. Autoimmun. Rev. 22(5), 103312 (2023).","journal-title":"Autoimmun. Rev."},{"issue":"12","key":"43240_CR12","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser, S. L. & Cree, B. A. C. Treatment of multiple sclerosis: A review. Am. J. Med. 133(12), 1380-1390.e2 (2020).","journal-title":"Am. J. Med."},{"key":"43240_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).","journal-title":"BMJ"},{"issue":"2","key":"43240_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 69(2), 292\u2013302 (2011).","journal-title":"Ann Neurol."},{"issue":"11","key":"43240_CR15","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33(11), 1444\u20131452 (1983).","journal-title":"Neurology"},{"key":"43240_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne, J. A. C. et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898 (2019).","journal-title":"BMJ"},{"issue":"3","key":"43240_CR17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin, L. & Chu, H. Quantifying publication bias in meta-analysis. Biometrics 74(3), 785\u2013794 (2018).","journal-title":"Biometrics"},{"issue":"1","key":"43240_CR18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12874-019-0829-2","volume":"19","author":"A B\u00e9liveau","year":"2019","unstructured":"B\u00e9liveau, A. et al. BUGSnet: An R package to facilitate the conduct and reporting of Bayesian network meta-analyses. BMC Med. Res. Methodol. 19(1), 196 (2019).","journal-title":"BMC Med. Res. Methodol."},{"key":"43240_CR19","unstructured":"Dias, S., et al., NICE decision support unit technical support documents. In NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials. (National Institute for Health and Care Excellence (NICE), 2014). Copyright \u00a9 2014 National Institute for Health and Clinical Excellence, unless otherwise stated. All rights reserved, London."},{"issue":"7","key":"43240_CR20","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1111\/ene.15314","volume":"29","author":"M Battaglini","year":"2022","unstructured":"Battaglini, M. et al. Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a. Eur. J. Neurol. 29(7), 2024\u20132035 (2022).","journal-title":"Eur. J. Neurol."},{"issue":"9268","key":"43240_CR21","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","volume":"357","author":"G Comi","year":"2001","unstructured":"Comi, G. et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet 357(9268), 1576\u20131582 (2001).","journal-title":"Lancet"},{"issue":"13","key":"43240_CR22","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJM200009283431301","volume":"343","author":"LD Jacobs","year":"2000","unstructured":"Jacobs, L. D. et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 343(13), 898\u2013904 (2000).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"43240_CR23","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.clineuro.2007.01.007","volume":"109","author":"MR Motamed","year":"2007","unstructured":"Motamed, M. R., Najimi, N. & Fereshtehnejad, S. M. The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis. Clin. Neurol. Neurosurg. 109(4), 344\u2013349 (2007).","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"6","key":"43240_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1600-0404.2007.00813.x","volume":"115","author":"H Pakdaman","year":"2007","unstructured":"Pakdaman, H. et al. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event. Acta Neurol. Scand. 115(6), 429\u2013431 (2007).","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"43240_CR25","first-page":"205521731984972","volume":"5","author":"TK Banerjee","year":"2019","unstructured":"Banerjee, T. K. et al. Conversion of clinically isolated syndrome to multiple sclerosis: A prospective multi-center study in Eastern India. Mult. Scler. J. Exp. Transl. Clin. 5(2), 2055217319849721 (2019).","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"43240_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102262","volume":"44","author":"J Kolcava","year":"2020","unstructured":"Kolcava, J. et al. Conversion of clinically isolated syndrome to multiple sclerosis: a prospective study. Mult. Scler. Relat. Disord. 44, 102262 (2020).","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"24 Suppl 4","key":"43240_CR27","first-page":"S12","volume":"68","author":"BW Thrower","year":"2007","unstructured":"Thrower, B. W. Clinically isolated syndromes: Predicting and delaying multiple sclerosis. Neurology 68(24 Suppl 4), S12\u2013S15 (2007).","journal-title":"Neurology"},{"issue":"10","key":"43240_CR28","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","volume":"24","author":"X Montalban","year":"2025","unstructured":"Montalban, X. et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 24(10), 850\u2013865 (2025).","journal-title":"Lancet Neurol."},{"issue":"4","key":"43240_CR29","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1177\/1120672120983179","volume":"31","author":"M Al-Namaeh","year":"2021","unstructured":"Al-Namaeh, M. Systematic review and meta-analysis of the development of multiple sclerosis in clinically isolated syndrome. Eur. J. Ophthalmol. 31(4), 1643\u20131655 (2021).","journal-title":"Eur. J. Ophthalmol."},{"issue":"6","key":"43240_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2217\/cer-2020-0267","volume":"10","author":"IA Samjoo","year":"2021","unstructured":"Samjoo, I. A. et al. Efficacy classification of modern therapies in multiple sclerosis. J. Comp. Eff. Res. 10(6), 495\u2013507 (2021).","journal-title":"J. Comp. Eff. Res."},{"issue":"3","key":"43240_CR31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","volume":"13","author":"TP Leist","year":"2014","unstructured":"Leist, T. P. et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): A phase 3 randomised trial. Lancet Neurol. 13(3), 257\u2013267 (2014).","journal-title":"Lancet Neurol."},{"issue":"5","key":"43240_CR32","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1212\/WNL.54.5.1145","volume":"54","author":"GP Rice","year":"2000","unstructured":"Rice, G. P., Filippi, M. & Comi, G. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 54(5), 1145\u20131155 (2000).","journal-title":"Neurology"},{"key":"43240_CR33","doi-asserted-by":"publisher","first-page":"175628561775336","DOI":"10.1177\/1756285617753365","volume":"11","author":"G Comi","year":"2018","unstructured":"Comi, G. et al. Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: The CLARITY Extension study. Ther. Adv. Neurol. Disord. 11, 1756285617753365 (2018).","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"5","key":"43240_CR34","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00415-018-8752-8","volume":"265","author":"X Armoiry","year":"2018","unstructured":"Armoiry, X. et al. Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: A systematic review of randomised controlled trials and network meta-analysis. J. Neurol. 265(5), 999\u20131009 (2018).","journal-title":"J. Neurol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43240-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43240-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43240-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:18:11Z","timestamp":1776813491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43240-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["43240"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-43240-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13087"}}